TryGOLD- Free

"Moving forward, cancer may not be a death threat but a manageable disease with strong control"
BioSpectrum Asia|BioSpectrum Asia Nov 2024
Cartherics Pty Ltd, a Melbourne-based biotechnology company led by renowned stem cell biologist and IVF pioneer Prof Alan Trounson, is , focusing on a portfolio of CAR-T and CAR-NK cell products.
- Ayesha Siddiqui
"Moving forward, cancer may not be a death threat but a manageable disease with strong control"

The company’s allogeneic (off-the-shelf) cell platform utilises induced pluripotent stem cells (iPSCs) generated from donated cord blood, which can be differentiated into NK cells, T cells, and other immune system cells. Cartherics' lead product, CTH-401, is an investigational allogeneic iPSC-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy designed to target solid tumours. Following a successful pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA), CTH-401 is set to enter clinical trials for ovarian cancer in 2025. Subject to early clinical data, CTH-401 will subsequently enter a basket trial targeting other TAG-72+ solid cancers. Prof. Alan Trounson, CEO of Cartherics, sheds light on iPSCs for CAR-T therapies, the future of immunotherapies, and the CGT landscape in the APAC region. Edited excerpts:

Could you explain more about the advantages of using iPSCs from cord blood for creating your ‘off-the-shelf’ CAR-NK and CAR-T therapies?

Umbilical cord blood contains pristine blood cells that have very few spontaneous or induced mutations, can be selected for homozygosity at the HLA locus, that provide the opportunity for transplant compatibility and can be turned into iPSCs that are immortal and can be directed into any cell of the body. These iPSCs can be easily geneedited and have exact editing and freedom from genetic changes by clonal derivation as a therapeutic product free of potential oncogenic inducers. The cells produced are exact clones of each other, much like a drug product. This can only be achieved with pluripotent stem cells. Directing the gene-edited iPSCs into CAR-T and CAR-NK products involves a proprietary method as is the manufacturing process. Consequently, we can use CAR-NK cells for allogeneic (off-the-shelf) therapy. CAR-T cells produced this way need further alteration for allogeneic therapy.

This story is from the BioSpectrum Asia Nov 2024 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the BioSpectrum Asia Nov 2024 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Prof. Christian Wolfrum to join NTU as Deputy President and Provost
BioSpectrum Asia

Prof. Christian Wolfrum to join NTU as Deputy President and Provost

Nanyang Technological University, Singapore (NTU Singapore) has announced that Professor Christian Wolfrum, an eminent biomedical scientist, will be joining the University as the next Deputy President and Provost.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Japan suggests addition of PVA into drugs for strong antitumour activity
BioSpectrum Asia

Japan suggests addition of PVA into drugs for strong antitumour activity

Treatment for more advanced and difficult-to-treat head and neck cancers can be improved with the addition of polyvinyl alcohol (PVA), the same ingredient used in children's glue.

time-read
1 min  |
BioSpectrum Asia Feb 2025
"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"
BioSpectrum Asia

"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"

2024 saw Japanese medtech firm Olympus receiving approval for the company's first cloud-based AI endoscopy devices in the US and Europe, marking a significant milestone in Olympus' efforts to enhance clinical outcomes and operational efficiency in endoscopy, paving the way to launch its upcoming endoscopy solution, the “Intelligent Endoscopy Ecosystem”.

time-read
5 mins  |
BioSpectrum Asia Feb 2025
BeiGene names Giancarlo Benelli as Head of Europe biz
BioSpectrum Asia

BeiGene names Giancarlo Benelli as Head of Europe biz

BeiGene, a Hong Kong-headquartered oncology company that intends to change its name to BeOne Medicines Ltd., has announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Korea develops innovative injectable adhesive hydrogel for bone regeneration
BioSpectrum Asia

Korea develops innovative injectable adhesive hydrogel for bone regeneration

A research team from South Korea-based Pohang University of Science and Technology or POSTECH's Department of Chemical Engineering and Graduate School of Convergence Science and Technology, along with the Department of Chemical Engineering, has developed an innovative injectable adhesive hydrogel for bone regeneration.

time-read
1 min  |
BioSpectrum Asia Feb 2025
When Clinical Trials Suffer From 'Complicated' Interactions
BioSpectrum Asia

When Clinical Trials Suffer From 'Complicated' Interactions

Diversity in culture, language, and data gathering methods will further increase the difficulty of clinical trials as they become more international, particularly with the growing number of sites being employed across China, Japan, South Korea, and India.

time-read
5 mins  |
BioSpectrum Asia Feb 2025
Dr Krishna M Ella receives prestigious INSA India fellowship
BioSpectrum Asia

Dr Krishna M Ella receives prestigious INSA India fellowship

Dr Krishna Ella, a distinguished scientist, co-founder and Executive Chairman of Bharat Biotech International, has been recognised with the prestigious India Fellowship of the Indian National Science Academy (INSA) for the year 2025, for his contributions to new knowledge, discoveries, development of new vaccine technologies, noteworthy improvement in existing technologies.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Bruker launches infrared imaging microscope for pharma and life science research
BioSpectrum Asia

Bruker launches infrared imaging microscope for pharma and life science research

US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade laser (QCL) based infrared (IR) imaging microscope.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities
BioSpectrum Asia

Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities

Qiagen has announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analysed from a single biological sample.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers
BioSpectrum Asia

Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers

US-based Repligen Corporation has announced the commercial launch of its CTech SoloVPE PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers.

time-read
1 min  |
BioSpectrum Asia Feb 2025

We use cookies to provide and improve our services. By using our site, you consent to cookies. Learn more